SIGFOX
6.1.2022 11:02:07 CET | Business Wire | Press release
Sigfox, a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer, today announces its partnership with HT Micron, a Brazilian expert in advanced semiconductor solutions, and Nowi, a semiconductor company that specializes in the development of energy harvesting power management technology, to explore and unlock the benefits of integrating energy harvesting into Sigfox devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005406/en/
This collaboration marks the first step for Sigfox towards a commercial development of energy harvesting modules to equip IoT devices and contribute to more sustainability in IoT. Key use cases are applications in Smart metering, industrial sensoring, asset tracking and air quality monitoring.
During the research phase, HT Micron has worked on creating the innovative semiconductor solution to be integrated with Nowi’s Energy Harvesting PMIC (Power Management Integrated Circuit) designed especially for low power IoT devices. Equipped on Sigfox devices and powered by the 0G technology, this solution will help reduce battery consumption and offer longer autonomy while reducing the total cost of ownership.
Nowi PMIC is designed to efficiently extract power from ambient energy sources like light and vibration to charge a variety of energy storage elements such as a rechargeable battery or a capacitor. It is best suited for most low power applications like distributed IoT sensors and TV remote controls for example.
“The low power consumption of Sigfox solutions is particularly well suited to being powered by ambient energy harvesting. As many Sigfox-based applications require intermittent communication intervals, this allows for trickle charging a storage element with energy harvesting in between transmissions ,” explains Chris Juliano, CCO at Nowi .
Sigfox and HT Micron have been working together for several years already and HT Micron was identified as a strategic partner for this project as they have the expertise to create innovative modules and they consider energy harvesting essential for IoT mass adoption with sustainability.
“We are glad to take this next step with Sigfox and explore energy harvesting solutions as a new way to create added value to our end customers and help them improve their environmental impact ,” says Edelweis Ritt, CIO at HT Micron .
“This collaboration with Nowi and HT Micron is another proof point towards our ambition to create IoT solutions that will help our clients preserve the environment by greatly reducing their energy consumption. We are looking forward to the development of this new kind of devices and to the positive impact they will generate ” says Benjamin Jooris, Client & Ecosystem Success Director at Sigfox.
The first step of this project is a development kit integrating Nowi’s PMIC solution with HT Micron’s Sigfox system-in-package, to be used for testing purposes by R&D and product development teams. First information will be presented at CES 2022 (5-7 January in Las Vegas) at Nowi’s booth (#51733) to gather customer and developers’ feedback. Customers can register to receive the development kit. Next, Sigfox, Nowi and HT Micron will create a mass production module that can be used by any type of device maker.
This announcement comes as part of strengthening Sigfox's strategy to help reduce the human impact on the environment with IoT, and it will be soon followed by other solutions based on energy harvesting as new projects are already in discussion.
****
About Sigfox
Sigfox is a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer. Sigfox offers a unique combination of ultra-low cost and ultra-low power solutions enabled by a single global network, owned and operated by 75 Sigfox Operators, enabling businesses to gain visibility and track their assets worldwide. With more than 19 million connected devices and 75 million messages sent a day, Sigfox helps its customers to extract data at the lowest cost of production and accelerate their digital transformation in key areas such as asset tracking and monitoring.
ISO 9001 certified and supported by a strong partner ecosystem, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore, and Tokyo.
About Nowi
Nowi is a semiconductor company founded in 2016, based in Delft, the Netherlands, with regional offices in the US and in Shanghai.
Nowi has developed energy harvesting power management ICs that combine top harvesting performance with the world’s smallest assembly footprint and lowest BOM cost. Thereby it simplifies the design process and lowers the threshold for any company to develop ‘Plug & Forget’ products.
About HT Micron
HT Micron provides advanced semiconductor solutions. The portfolio includes memories for computers, cell phones and smart TVs, as well as System-in-Package connectivity solutions for the Internet of Things. HT Micron is a Brazilian company, having as the main shareholder the South Korean group HANA Micron, and is based in the city of São Leopoldo, RS, in South Brazil.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005406/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom